Project number: 101221750
Project value: 1,403,931 EUR
Project duration: 01/04/2026 – 31/03/2031
Project manager: Mykhailo Batiuk, PhD
Post-Traumatic Stress Disorder (PTSD) is a debilitating psychiatric condition triggered by severe psychological trauma, affecting 4% of the global population—a figure expected to rise amid ongoing global conflicts, such as the war in Ukraine. Despite its widespread impact, effective treatments remain limited, posing a significant burden on individuals and society alike.
Dr. Batiuk’s research addresses this challenge by focusing on a key biological mechanism of PTSD: epigenetics. Epigenetics can be understood as a molecular layer of “switches” that sit above the DNA sequence. While trauma does not alter the genetic code itself, it can flip these molecular switches, changing how brain cells function and ultimately triggering the symptoms of PTSD.
The project will employ state-of-the-art single-cell genomics technologies to analyze epigenetic dysregulation in the human brain. This high-resolution approach will enable the identification of specific brain cell types and precise epigenetic switches associated with PTSD, highlighting the most promising new therapeutic targets.
Based on these key human data, the team will develop a new, precision animal model of PTSD, designed to test targeted therapies aimed at resetting the identified epigenetic switches. The model will serve as a robust platform for evaluating the efficacy of novel therapeutic strategies in alleviating PTSD symptoms.
The ultimate goal of the project is to lay the groundwork for breakthrough therapies capable of reducing suffering and restoring hope to individuals affected by trauma.
Located strategically in Wrocław, near Ukraine, and within a large refugee community, Łukasiewicz – PORT Polish Center for Technology Development provides an exceptional environment for studying PTSD pathology and addressing its growing societal relevance.
With state-of-the-art research infrastructure, highly skilled scientific teams, and a strong commitment to translational biomedical research, Łukasiewicz – PORT is uniquely positioned to advance innovative biomedical projects and translate scientific discoveries into clinical solutions that enhance patient care and quality of life.
